Sign in
CompletedNo phase

Acute Intermittent Hypoxia in Traumatic Brain Injury

Key facts

Who runs it
Shirley Ryan AbilityLab
Where
Chicago, United StatesSee the site
Trial code
Status
Completed
People taking part
12 people enrolled
Started
15 Mar 2022
Ended
29 Jan 2024
Type of study
Interventional
Treatments tested
  • Acute Intermittent Hypoxia
Record updated
18 February 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Aged 18-65 years
  • A first time, mild to moderate traumatic brain injury (TBI) confirmed by medical records
  • When available, a Glasgow Coma Scale score between 9-15
  • Able to use a keyboard
  • Able to understand and communicate in English
  • Able to consent independently
  • Able to leave a research visit with a companion/group transportation
  • Women of child-bearing age must be comfortable confirming a negative pregnancy prior to participating in the study
  • Not involved in any other research intervention study testing neurobehavioral functioning

Who cannot take part

  • Other neurological diagnoses or a diagnosis of severe psychiatric disorder (e.g., psychosis) or a reported childhood learning disability
  • Pre-existing hypoxic pulmonary disease
  • Severe hypertension (>160/100)
  • Medically documented history of obstructive lung diseases [e.g., Chronic obstructive pulmonary disease (COPD) or significant asthma]
  • Ischemic cardiac disease
  • Severe aphasia, preventing a participant from understanding the protocol and consent form
  • Ineligible to undergo MRI or TMS

Where in United States

  • Shirley Ryan AbilityLabChicago, United States

About the trial

What the trial wants to find out

This study is designed to answer questions related to safety and preliminary efficacy of Acute Intermittent Hypoxia (AIH) in Traumatic Brain Injury (TBI) survivors. First, we aim to establish whether brief reductions in inhaled oxygen concentration can be safely tolerated in TBI survivors. Second, we aim to establish whether there are any effects of AIH on memory, cognition, and motor control. Participants will be monitored closely for any adverse events during these experiments. Data will be analyzed to determine if there is an improvement in key outcomes at any dose level.

The group in the trial

  • AIH groupTreatment being tested

    Hypoxia will be administered via a specialized face mask attached to a gas mixing device (HYP123, Hypoxico Inc.), which controls oxygen content in inhaled air. The hypoxia administering unit will be manually adjusted to supply O2 at the target level for a given session (approximately 21%-normal room air, 17%, 13%, and 9% respectively). Each session will include 15 cycles of hypoxia, each lasting up to 60 seconds, interspersed with up to 90-second normoxic episodes. An oxygen monitor will continuously measure and record the fraction of inspired oxygen delivered (MAX-250E, Maxtec Inc.).

    Treatment: Acute Intermittent Hypoxia

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Cognitive Effects of Acute Intermittent Hypoxia-Induced Neuroplasticity in Traumatic Brain Injury
Record updated
18 February 2026